预防和治疗高原病药物临床用药参考

马骏; 樊鹏程; 张强; 马慧萍; 王荣; 贾正平

doi:10.3969/j.issn.1006-0111.2013.04.002

预防和治疗高原病药物临床用药参考

doi: 10.3969/j.issn.1006-0111.2013.04.002

兰州军区兰州总医院药剂科, 甘肃兰州 730050

基金项目: 国家科技重大专项(军特药保密专项)(2008ZXJ09014-010).

Clinical pharmacology in the prophylaxis and treatment of high-altitude illness

Department of Pharmacy, General Hospital of Lanzhou Command, Lanzhou 730050, China

摘要: 本文针对乙酰唑胺、地塞米松、硝苯地平、西地那非和沙美特罗5种药物,在治疗急性高原病、高原脑水肿、高原肺水肿及伴随其他疾病情况下的高原病,就如何选择和使用这些药物进行综述。讨论了正常的给药剂量,当病人患有肾功能不全、肝功能不全、其他疾病以及存在药物相互作用情况下,就如何选择用药和剂量调整进行阐述。通过对上述问题的充分考虑,医生在救治病人时可以提高合理用药水平和治疗成功率,使病人安全愉快地在高原旅行。
- 乙酰唑胺 /
- 地塞米松 /
- 硝苯地平 /
- 西地那非 /
- 沙美特罗 /
- 急性高山病 /
- 高原脑水肿 /
- 高原肺水肿
Abstract: The use choice of acetazolamide, dexamethasone, nifedipine, sildenafil, and salmeterol in the management of altitude illness such as acute mountain sickness, high-altitude cerebral edema, high-altitude pulmonary edema, and with underlying medical problems were reviewed. The indications and dosing recommendations for individuals without underlying disease were discussed, and drug selection or dosing regimens were considered which would be affected by the presence of renal insufficiency, hepatic insufficiency, other important medical conditions, and the potential for drug interactions. These issues should be taken adequate consideration; so clinicians could increase the chances that properly healed patients with underlying medical conditions who could enjoy a safe trip to high altitude.
- acetazolamide /
- dexamethasone /
- nifedipine /
- sildenafil /
- salmeterol /
- acute mountain sickness /
- high-altitude cerebral edema /
- high-altitude pulmonary edema

[1]	Maggiorini M, Brunner-La RHP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema:a randomized trial[J]. Ann Intern Med, 2006, 145:497.
[2]	Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema[J]. N Engl J Med, 2002, 346:1631.
[3]	Teppema LJ, Balanos GM, Steinback CD, et al. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia[J]. Am J Respir Crit Care Med, 2007, 175:277.
[4]	Hackett PH, Roach RC. High-altitude illness[J]. N Engl J Med, 2001, 345:107.
[5]	Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness[J]. Chest, 2008, 133:744.
[6]	Pepys MB. Acetazolamide and renal stone formation[J]. Lancet, 1970, 1:837.
[7]	van Bortel L, Bohm R, Mooij J, et al. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure[J]. Eur J Clin Pharmacol, 1989, 37:185.
[8]	Swan SK, Bennett WM. Drug dosing guidelines in patients with renal failure[J]. West J Med, 1992, 156:633.
[9]	Forgue ST, Phillips DL, Bedding AW, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics[J]. Br J Clin Pharmacol, 2007, 63:24.
[10]	Muirhead GJ, Wilner K, Colburn W, et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil[J]. Br J Clin Pharmacol, 2002, 53(suppl 1):21S.
[11]	Grossman EB, Swan SK, Muirhead GJ, et al. The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients[J]. Kidney Int, 2004, 66:367.
[12]	Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol[J]. Clin Pharmacokinet, 2002, 41:19.
[13]	Dawson AM, De Groote J, Rosenthal WA, et al. The effects of diamox ammonia metabolism in liver disease[J]. Clin Sci (Lond), 1957, 16:413.
[14]	Ene MD, Roberts CJ. Pharmacokinetics of nifedipine after oral administration in chronic liver disease[J]. J Clin Pharmacol, 1987, 27:1001.
[15]	Kleinbloesem CH, van Harten J, Wilson JP, et al. Nifedipine:kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration[J]. Clin Pharmacol Ther, 1986, 40:21.
[16]	Callejas RJL, Salmeron Escobar J, Gonzalez-Calvin J, et al. Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil[J]. Liver Transpl, 2006, 12:690.
[17]	Wang YW, Lin HC, Yang YY, et al. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension[J]. J Gastroenterol, 2006, 41:593.
[18]	Finley DS, Lugo B, Ridgway J, et al. Fatal variceal rupture after sildenafil use:report of a case[J]. Curr Surg, 2005, 62:55.
[19]	Manchee GR, Eddershaw PJ, Ranshaw LE, et al. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A[J]. Drug Metab Dispos, 1996, 24:555.
[20]	Swenson ER. Carbonic anhydrase inhibitors and ventilation:a complex interplay of stimulation and suppression[J]. Eur Respir J, 1998, 12:1242.
[21]	Coudon WL, Block AJ. Acute respiratory failure precipitated by a carbonic anhydrase inhibitor[J]. Chest, 1976, 69:112.
[22]	Brubaker PL. Adventure travel and type 1 diabetes:the complicating effects of high altitude[J]. Diabetes Care, 2005, 28:2563.
[23]	Stuiver PC, Goud TJ. Corticosteroids and liver amoebiasis[J]. BMJ, 1978, 2:394.
[24]	Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population[J]. Clin Microbiol Rev, 2004, 17:208.
[25]	Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease[J]. N Engl J Med, 1983, 309:21.
[26]	Wu TY, Liu JL. Alcohol and aspirin in combination with dexamethasone causes gastrointestinal bleeding at high altitude[J]. Wilderness Environ Med, 2006, 17:69.
[27]	Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease:a randomized crossover trial[J]. JAMA, 2002, 287:719.
[28]	Fox KM, Thadani U, Ma PT, et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina[J]. Eur Heart J, 2003, 24:2206.
[29]	Petersen KU, Jaspersen D. Medication-induced oesophageal disorders[J]. Expert Opin Drug Saf, 2003, 2:495.
[30]	Sweeney KR, Chapron DJ, Brandt JL, et al. Toxic interaction between acetazolamide and salicylate:case reports and a pharmacokinetic explanation[J]. Clin Pharmacol Ther, 1986, 40:518.
[31]	Hill JB. Experimental salicylate poisoning:observations on the effects of altering blood pH on tissue and plasma salicylate concentrations[J]. Pediatrics, 1971, 47:658.
[32]	Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine:an update[J]. Clin Pharmacokinet, 1996, 31:198.
[33]	Tabbara KF, Al-Faisal Z, Al-Rashed W. Interaction between acetazolamine and cyclosporine[J]. Arch Ophthalmol, 1998, 116:832.
[34]	Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives[J]. Biomed Pharmacother, 1986, 40:301.
[35]	Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs[J]. Am J Cardiovasc Drugs, 2004, 4:281.
[36]	Kaplan RC, Heckbert SR, Koepsell TD, et al. Use of calcium-channel blockers and risk of hospitalized gastrointestinal tract bleeding[J]. Arch Intern Med, 2000, 160:1849.
[37]	Wu TY, Ding SQ, Liu JL, et al. High-altitude gastrointestinal bleeding:an observation in Qinghai-Tibetan railroad construction workers on Mountain Tanggula[J]. World J Gastroenterol, 2007, 13:774.
[38]	Smith M, Lin KM, Zheng YP. An open-trial of nifedipineherb interactions:nifedipine with St. John's wort, ginseng, or gingko biloba[J]. Clin Pharmacol Ther, 2001, 69:86.
[39]	Demaziere J, Fourcade JM, Busseuil CT, et al. The hazards of chloroquine self prescription in West Africa[J]. J Toxicol Clin Toxicol, 1995, 33:369.

[1]	闻韬, 焦广洋, 赵梦沛, 岳小强, 张凤, 陈万生. 基于UHPLC-Q-TOF/MS结合网络药理学研究柴胡桂枝干姜汤治疗慢性非萎缩性胃炎的物质基础及疗效机制 . 药学实践与服务, 2025, 43(): 1-9. doi: 10.12206/j.issn.2097-2024.202312061
[2]	柯刚, 董清科, 肖世容, 龚茜, 李荣, 汪代杰. 基于网络药理学探讨参苓白术散治疗肿瘤恶病质的作用机制 . 药学实践与服务, 2025, 43(5): 242-250. doi: 10.12206/j.issn.2097-2024.202208115
[3]	邵尉, 袁妮, 刘叶, 于飞, 柳莹, 王峰. 丙戊酸钠与左乙拉西坦治疗儿童癫痫病的成本-效果分析 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202408046
[4]	曹金发, 钟玲, 何苗, 田泾. 炎症性肠病合并心房颤动患者的用药分析与监护 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202403004
[5]	张俊丽, 李媛媛, 尹静, 杨鸿源, 白耀武. 咪达唑仑调节PINK1/PARKIN信号通路对缺血性脑卒中大鼠神经元损伤的影响 . 药学实践与服务, 2025, 43(6): 1-6. doi: 10.12206/j.issn.2097-2024.202405024
[6]	王文涛, 高兴, 赵凤平, 郑灿辉, 陈新. 异硒唑酮类化合物在疾病治疗中的作用和化学合成方法研究 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202308064
[7]	周娇, 郑建雨, 王思真, 杨峰. mRNA肿瘤疫苗非病毒递送系统研究进展 . 药学实践与服务, 2025, 43(3): 109-116. doi: 10.12206/j.issn.2097-2024.202410034
[8]	张紫璇, 高苑, 张利, 李佳莉, 徐希科, 祖先鹏. 中药防治急性肺损伤的活性成分及其作用机制研究进展 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202404079
[9]	孟园园, 吴芸杨, 陈婷如, 顾秦五风, 杨延龙. 九味永安颗粒联合西替利嗪治疗湿疹湿热蕴肤证的临床疗效观察 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202407045
[10]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[11]	徐飞, 陈瑾, 鲁育含, 李志勇. 肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
[12]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[13]	杨嘉宁, 赵一颖, 肖伟. 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
[14]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[15]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[16]	丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉. 消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
[17]	张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳. 基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 445-450. doi: 10.12206/j.issn.2097-2024.202403057
[18]	杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯. 瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026
[19]	史生辉, 石飞, 雷琼, 王亚峰, 吴雪花. 青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
[20]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050

点击查看大图

计量

文章访问数: 4558
HTML全文浏览量: 1252
PDF下载量: 85
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

预防和治疗高原病药物临床用药参考

doi: 10.3969/j.issn.1006-0111.2013.04.002

Clinical pharmacology in the prophylaxis and treatment of high-altitude illness

计量

预防和治疗高原病药物临床用药参考

doi: 10.3969/j.issn.1006-0111.2013.04.002

兰州军区兰州总医院药剂科, 甘肃兰州 730050

English Abstract

Clinical pharmacology in the prophylaxis and treatment of high-altitude illness

Department of Pharmacy, General Hospital of Lanzhou Command, Lanzhou 730050, China

全文HTML

目录

留言板

预防和治疗高原病药物临床用药参考

doi: 10.3969/j.issn.1006-0111.2013.04.002

Clinical pharmacology in the prophylaxis and treatment of high-altitude illness

计量

出版历程

预防和治疗高原病药物临床用药参考

doi: 10.3969/j.issn.1006-0111.2013.04.002

兰州军区兰州总医院药剂科, 甘肃 兰州 730050

English Abstract

Clinical pharmacology in the prophylaxis and treatment of high-altitude illness

Department of Pharmacy, General Hospital of Lanzhou Command, Lanzhou 730050, China

全文HTML

目录

兰州军区兰州总医院药剂科, 甘肃兰州 730050